Functional and biochemical characterization of the baculovirus caspase inhibitor MaviP35

IA. Brand1, MM Green1,4, S Civciristov1,4, D Pantaki-Eimany1,4, C George1, TR Gort2, N Huang2, RJ Clem2 and CJ Hawkins*,1,3

Many viruses express proteins which prevent the host cell death that their infection would otherwise provoke. Some insect viruses suppress host apoptosis through the expression of caspase inhibitors belonging to the P35 superfamily. Although a number of P35 relatives have been identified, Autographa californica (Ac) P35 and Spodoptera littoralis (Spli) P49 have been the most extensively characterized. AcP35 was found to inhibit caspases via a suicide substrate mechanism: the caspase cleaves AcP35 within its ‘reactive site loop’ then becomes trapped, irreversibly bound to the cleaved inhibitor. The Maruca vitrata multiple nucleopolyhedrovirus encodes a P35 family member (MaviP35) that exhibits 81% identity to AcP35. We found that this relative shared with AcP35 the ability to inhibit mammalian and insect cell death. Caspase-mediated cleavage within the MaviP35 reactive site loop occurred at a sequence distinct from that in AcP35, and the inhibitory profiles of the two P35 relatives differed. MaviP35 potently inhibited human caspases 2 and 3, DCP-1, DRICE and CED-3 in vitro, but (in contrast to AcP35) only weakly suppressed the proteolytic activity of the initiator human caspases 8, 9 and 10. Although MaviP35 inhibited the AcP35-resistant caspase DRONC in yeast, and was sensitive to cleavage by DRONC in vitro, MaviP35 failed to inhibit the proteolytic activity of bacterially produced DRONC in vitro.

Cell Death and Disease (2011) 2, e242; doi:10.1038/cddis.2011.127; published online 15 December 2011
Subject Category: Cancer

Received 01.11.11; accepted 14.11.11; Edited by P Salomoni

1Department of Biochemistry, La Trobe Institute for Molecular Science, La Trobe University, Bundoora, Victoria, Australia; 2Division of Biology, Kansas State University, Manhattan, KS, USA and 3Children’s Cancer Centre, Murdoch Children’s Research Institute, Royal Children’s Hospital, Parkville, Australia
*Corresponding author: CJ Hawkins, Department of Biochemistry, La Trobe University, Kingsbury Drive, Bundoora, Victoria 3086, Australia.
þThese authors contributed equally to this work.

Keywords: caspase; P35; baculovirus; apoptosis; infection; virus

Abbreviations: Mavi, Maruca vitrata; MNPV, multiple nucleopolyhedrovirus; Ac, Autographa californica; Bm, Bombyx mori; NPV, nucleopolyhedrovirus; Spli, Spodoptera littoralis; TRAIL, TNF-related apoptosis-inducing ligand; FBS, fetal bovine serum; MEF, mouse embryonic fibroblast; Xgal, 5-bromo-4-chloro-3-indolyl-Cl-A-galactopyranoside; CAT, chloramphenicol acetyl transferase; RFU, relative fluorescence units

Functional and biochemical characterization of the baculovirus caspase inhibitor MaviP35

Functional and biochemical characterization of the baculovirus caspase inhibitor MaviP35
caspase 3, although lower BmP35 expression levels may have contributed to this difference.\textsuperscript{13} No quantitative data have been published regarding the caspase inhibitory potency or specificity of BmP35, and no other close relatives of AcP35 have been functionally or biochemically investigated to date.

Some baculoviruses encode distant relatives of AcP35, which constitute the P49 subfamily. \textit{Spodoptera littoralis} (Spli) NPV-P49 is the best-studied member of this subfamily. Like AcP35, SpliP49 is a broad-spectrum caspase inhibitor that could suppress insect\textsuperscript{17–20} and mammalian\textsuperscript{21} cell death. Unlike AcP35, SpliP49 could inhibit DRONC-mediated yeast lethality,\textsuperscript{21} but it was incapable of preventing DRICE processing in \textit{Drosophila} cells.\textsuperscript{19} SpliP49 could, however, prevent processing of executioner \textit{Spodoptera} caspases,\textsuperscript{18,20} implying that it can inhibit the proposed Sf-caspase-X. AcP35 contains the cleavage sequence DQMD’G within its reactive site loop, but SpliP49 instead possesses the sequence TVTD’G at this position. This sequence is required for SpliP49 to inhibit the distant insect caspase Sf-caspase-X, but its insertion into the AcP35 reactive site loop failed to confer this capability,\textsuperscript{20} indicating that other regions of the SpliP49 protein, not shared by AcP35, are critical for its ability to inhibit insect initiator caspases. The caspase inhibitor AMVP33 from \textit{Amsacta moorei} entomopoxovirus is the least homologous member of the P35 superfamily, exhibiting only 25% amino acid identity to AcP35.\textsuperscript{4}

The baculovirus \textit{Maruca vitrata} (Mavi) MNPV infects the legume pod borer \textit{Maruca vitrata}, and may offer a biological means of controlling this important pest of legume crops.\textsuperscript{22} The recent sequencing of the \textit{Mavi/MNPV} genome\textsuperscript{23} revealed the presence of a P35 ortholog (MaviP35). The predicted MaviP35 protein is highly homologous to AcP35, but its predicted reactive site loop possesses a distinct caspase cleavage sequence. Here, we report our characterization of the apoptosis and caspase inhibitory properties of MaviP35.

**Results**

Sequencing of the \textit{Mavi/MNPV} genome\textsuperscript{23} revealed that this virus encoded a P35 ortholog that was 81% identical to the founding member of this family, AcP35 (Figures 1a and b), and modeling suggested the two relatives may adopt similar structures (Figures 1c and d). Residues determined to be essential for the caspase inhibitory activities of AcP35, including C2\textsuperscript{8} and D87,\textsuperscript{24,25} were conserved in MaviP35, suggesting it too may function as a caspase inhibitor that could prevent apoptosis. We tested this hypothesis by overexpressing MaviP35 in mammalian and insect cells, and monitoring the transfectants’ sensitivity to apoptosis. MaviP35 inhibited insect cell death and caspase activity triggered by infection with an AcP35-deficient baculovirus, although less efficiently than AcP35 (Figures 2a and b). MaviP35 and AcP35 inhibited insect cell death induced by actinomycin D to a similar extent (Figure 2c), but MaviP35 protected a larger proportion of insect cells than AcP35 against apoptosis induced by UV irradiation (Figure 2d). MaviP35 and AcP35 afforded similar levels of protection to mammalian cells against cisplatin-induced apoptosis (Figure 2e), but MaviP35 was less protective than AcP35 against death induced by TNF-related apoptosis-inducing ligand (TRAIL; Figure 2f).

We have previously exploited yeast-based assays to visualize caspase activity and inhibition, and these were used to provide an indication of the specificity of MaviP35 for various caspases. MaviP35 protected yeast from death induced by mammalian caspases 1, 2, 3, 5, 7 and 8, the \textit{Drosophila} caspases DCP-1 and DRICE, and CED-3 from \textit{Caenorhabditis elegans} (Figure 3). In this system, MaviP35 appeared to exhibit similar activity to AcP35, and protected yeast from death induced by caspases 5, 8 and CED-3 better than SpliP49 (Figure 3).

AcP35 has been shown to inhibit caspases via a pseudo-substrate mechanism, and mutation of the caspase cleavage site abolishes caspase and apoptosis inhibitory activity.\textsuperscript{7,8} Comparison of the MaviP35 and AcP35 sequences predicted that caspases may cleave MaviP35 after residue D\textsuperscript{87} within the site TQFD\textsuperscript{87}G (Figure 1a). Consistent with this residue being critical for caspase inhibition, a putative P1 mutant failed to prevent DRICE induced yeast death (Figure 4). Lysates from yeast expressing active DRICE exhibited considerable DEVDase activity. Co-expression of untagged or carboxyl terminally FLAG-tagged wild-type MaviP35 or AcP35 abolished this activity, but their cleavage site mutants had negligible impact (Figure 4). Immunoblotting confirmed that the tagged mutants were expressed at least as abundantly as their wild-type counterparts. Interestingly, cleavage products could not be detected in lysates from yeast co-expressing DRICE with either MaviP35-FLAG or AcP35-FLAG. Because DRICE activity in this system is generated through auto-activation, we suspect that only relatively few P35 molecules would be required to block this feedback loop, and immunoblotting may not be sufficiently sensitive to detect this small number of cleaved proteins.

The yeast system is a sensitive tool for observing caspase inhibition within a naive eukaryotic environment, but only provides limited insight into the strength of inhibition. To gain a quantitative understanding of MaviP35’s caspase inhibitory activity, we purified FLAG-tagged MaviP35 and AcP35 and examined their ability to prevent recombinant caspases from cleaving fluorogenic substrates \textit{in vitro}. When present at 100–1000-fold excess, MaviP35 diminished by at least 90% the activity of caspases 2, 3, DRICE, DCP-1 and CED-3. Weaker inhibition was seen for caspases 1 and 7. MaviP35 only partially reduced the activity of caspases 6, 8 and 9, and negligible inhibition of caspase 10 was observed (Figure 5). A particularly striking difference between AcP35 and MaviP35 related to inhibition of caspase 8. As observed previously,\textsuperscript{26} AcP35 potently suppressed the proteolytic activity of this enzyme, yet a 100-fold excess of MaviP35 only decreased its activity by about half (Figure 5).

The alignment of P35 subfamily members revealed that the P4 and P2 residues differed between AcP35 and MaviP35 (P4-DQMD-P1 versus P4-TQFD-P1, respectively). Mutagenesis studies of AcP35 had previously demonstrated that changing its P4 aspartate residue to either alanine or asparagine markedly impaired its ability to inhibit caspases 3 and 8,\textsuperscript{7} highlighting the importance of the P4 amino acid for caspase inhibition. The cleavage site of MaviP35, containing a P4 threonine residue, was reminiscent of the site at which
DRONC auto-processes between its large and small subunit (TQTE)\(^1\) and, to a lesser extent, the caspase cleavage site within the SpliP49 reactive site loop (TVTD).\(^{17}\) This prompted us to wonder whether MaviP35 may be the first example of a P35 subfamily member that can inhibit DRONC. Consistent with this notion, expression of MaviP35 completely abolished DRONC-mediated yeast death (Figure 6a) and recombinant DRONC could cleave purified MaviP35, although not as
We therefore sought to determine whether MaviP35 could suppress DRONC activity in insect cells. DRONC can cleave DRICE between its large and small subunits and cleavage of DRICE in Drosophila cells has previously been used as a readout of DRONC activity. A GFP-tagged active site mutant of DRICE expressed in Drosophila Kc167 cells was completely processed to yield a 39-kDa product following actinomycin D treatment (Figure 6d), as expected from DRONC cleavage between the large and small subunits of DRICE (Figure 6e). Enforced expression of DIAP1 completely inhibited cleavage of DRICEC211A-eGFP in actinomycin D-treated Drosophila cells (Figure 6). Curiously, AcP35 partially inhibited

Figure 2 MaviP35 inhibits mammalian and insect cell death. (a, b) Sf9 cells were transfected with plasmids encoding MaviP35-FLAG, AcP35-FLAG or chloramphenicol acetyl transferase (CAT), then infected with an AcP35-mutant baculovirus. Untransfected cells were subjected to mock infection. (a) Survival was monitored relative to the mock-infected cells. (b) Caspase activity was detected and expressed relative to the DEVDase activity in infected cells expressing the negative control CAT protein. (c and d) S21 cells were co-transfected with plasmids encoding GFP and the specified proteins. After 4 h heat shock-mediated induction of transgene expression, the cells were treated with actinomycin D (c) or UV (d). Viability is expressed as the number of GFP-positive cells following exposure to apoptotic stimuli, relative to their number before treatment. (e and f) MEF (e) or LN18 glioblastoma cells (f) were co-transfected with a β-galactosidase expression plasmid and either an empty vector (solid lines), or plasmids encoding MaviP35 (dashed lines) or AcP35 (dotted lines), before treatment with the indicated doses of either cisplatin (e) or crosslinked TRAIL (f). Following 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside staining, the survival of blue (transfected) cells was scored using morphological criteria. Over 80 (e) or 150 (f) blue cells were scored for each condition per experiment. Error bars represent S.E.M. from three separate experiments (a–f).

Figure 3 MaviP35 inhibits caspase-dependent yeast death. Yeast were transformed with the indicated expression plasmids. Suspensions containing equivalent concentrations of each transformant were serially diluted and 5 μl of each dilution were spotted onto plates containing galactose (to induce transgene expression) or glucose (to repress transgene expression). Growth on inducing plates indicates survival and proliferation of yeast expressing the transgenes.

Characterization of MaviP35

efficiently as DRICE (Figures 6b and c). We therefore sought to determine whether MaviP35 could suppress DRONC activity in insect cells. DRONC can cleave DRICE between its large and small subunits and cleavage of DRICE in Drosophila cells has previously been used as a readout of DRONC activity. A GFP-tagged active site mutant of DRICE expressed in Drosophila Kc167 cells was completely processed to yield a 39-kDa product following actinomycin D treatment (Figure 6d), as expected from DRONC cleavage between the large and small subunits of DRICE (Figure 6e). Enforced expression of DIAP1 completely inhibited cleavage of DRICEC211A-eGFP in actinomycin D-treated Drosophila cells (Figure 6). Curiously, AcP35 partially inhibited
less potently than AcP35. Purified MaviP35 did not impair the ability of recombinant DRONC to cleave a peptide substrate (Figure 6f). Using a range of substrate and inhibitor concentrations, inhibition by bacterially produced DRONC of MaviP35 was extremely weak (Figure 7). Quantitation of MaviP35's inhibition of other caspases confirmed the data shown in Figure 5: strong inhibition of executioner caspases, but weak to negligible inhibition of initiator caspases (Figure 7c).

**Discussion**

This study describes the apoptosis and caspase inhibitory properties of a new P35 subfamily member: MaviP35. Like AcP35, MaviP35 could inhibit insect and mammalian cell death, was susceptible to caspase cleavage, and could inhibit the proteolytic activity of caspases. Nevertheless, AcP35 and MaviP35 differed in their specificity profile. MaviP35 inhibited executioner apoptotic caspases with similar potency to AcP35. However, MaviP35 was substantially less potent than AcP35 at inhibiting mammalian caspases 8 and 10. This may explain the weaker protection afforded by MaviP35 relative to AcP35 against TRAIL-induced cell death. MaviP35 was also a weaker inhibitor of recombinant caspase 9 than AcP35. However, it is important to note that published data suggest that the susceptibility of recombinant caspase 9 to AcP35 in vitro is not mirrored by apoptosome-activated caspase 9 within cell lysates, so it is possible that AcP35 and MaviP35 are both incapable of interfering with the activity of naturally activated caspase 9 in vivo.

The P4 residue of MaviP35 (threonine) differs from that of AcP35 (aspartate). Mutation of P4 in AcP35 to asparagine reduced its ability to inhibit caspase 3 by 47-fold, yet MaviP35—which contains the slightly larger polar uncharged residue threonine at this position— inhibited caspase 3 with similar efficiency to wild-type AcP35. Presumably differences in other regions of the protein compensate, allowing MaviP35 to efficiently suppress caspase 3 activity. The MaviP35 cleavage site resembles the auto-processing site between the large and small subunits of DRONC, and MaviP35 was sensitive to DRONC proteolysis in vitro. MaviP35 inhibited yeast death triggered by high-level expression of DRONC, suggesting that it could function as a pseudo-substrate inhibitor of DRONC. However, two pieces of evidence argue against this possibility. First, MaviP35 was an extremely weak inhibitor of recombinant DRONC activity in vitro. Its $K_i$ was indistinguishable from that of AcP35, which was incapable of inhibiting DRONC in yeast and in vivo and was resistant to DRONC cleavage in vitro. Second, MaviP35 only partially inhibited actinomycin D-induced cleavage of the DRICEC211A-eGFP fusion protein, impeding processing to a lesser extent than AcP35. This result implies that actinomycin D treatment provoked DRONC-mediated (AcP35/MaviP35 resistant) processing of the DRICE-eGFP substrate in Kc167 cells, but also suggested that other proteases, sensitive to AcP35/MaviP35 inhibition, also contributed to this proteolysis. Taken together, these data lead us to postulate that MaviP35 functions as a classical substrate for DRONC, rather than as a suicide substrate inhibitor. It is possible that the ability of MaviP35 to suppress DRONC-mediated yeast lethality reflects substrate competition: DRONC’s proteolytic attention may be diverted to MaviP35 processing rather than cleavage of essential yeast proteins.

Despite the high homology between MaviP35 and AcP35, this study has revealed an important difference in their caspase specificity. Both inhibitors could suppress downstream caspases from insects and mammals (and CED-3), but only AcP35 could efficiently block the activities of mammalian caspases-8 and -10. Neither AcP35 nor MaviP35 could significantly inhibit the Drosophila initiator caspase DRONC.
Materials and Methods

Sequence comparisons and structural modeling. Sequences of the P35 subfamily members were aligned using the ‘Multialign’ program and formatted using Jalview 2.0. Genbank accession numbers for the P35 sequences used were: MaviMNPV: YP_950833, AcMNPV: NP_054165.1, RoMNPV: NP_703122, BmNPV: AA012972, HcyMNPV: AA012972, SpliNPV: CAATX304 and LeseNPV: AAF78504. Protein Homology/analogy Recognition Engine (Phyre) was used to predict the structure of MaviP35. AcP35 and predicted MaviP35 structures were depicted using Jmol: an open-source Java viewer for chemical structures in 3D (http://www.jmol.org/).

Plasmid construction. For yeast experiments, coding DNA sequences were expressed from inducible Gal1/10 promoters. Plasmids-expressing caspase 2, caspase 3/lat2, caspase 5, caspase 7, caspase 8, CED-3, reverse DRICE, DCP-1, DRONC, AcP35, AcP35-F, AcP35-D87A-F and SplI49-F have been described previously. Other plasmids were generated as follows: the caspase 1 coding region was amplified using oligonucleotides 1 and 2 from pET21b-Casp-1-His (purchased from Addgene Cambridge, MA, USA). The product was cut with BamHI/XbaI and ligated into pGALL-(LEU2) cut with BamHI/XbaI. The MaviP35 coding region was amplified with oligonucleotides 3 and 4 from a plasmid kindly donated by Prof. Chung-Hsiung Wang, cut with BamHI/XhoI and ligated into pGALL-(HIS3) cut with BamHI/XhoI. MaviP35 was also amplified with oligonucleotides 3 and 5 and cloned the same way into pGALL-(HIS3), to incorporate a carboxyl terminal FLAG tag. Site-directed mutagenesis to generate MaviP35-D87A was performed using PCR. After excising MaviP35 from pGALL-(HIS3)-MaviP35 and inserting it into Bluescript II SK, a PCR was conducted using MaviP35-F as a template (oligonucleotides 6 and 7) to amplify the 3' portion of the gene incorporating a P1 mutation. This product was cut with

Figure 5 MaviP35 inhibits recombinant caspases in vitro. Cleavage of fluorogenic substrates by purified recombinant caspases (at the indicated concentrations) is plotted as the change in RFU per minute, in the presence of 1 μM of FLAG-tagged MaviP35, AcP35 or truncated CED-9 (a cytosolic protein devoid of caspase inhibitory activity). The dotted line indicates 10% activity, relative to the substrate cleavage rate in the presence of the control protein.
Boll/XhoI and inserted into Boll/XhoI cut MaviP35-Bluescript II SK ++. The resulting P1-mutated MaviP35-F gene was then excised with BamHI/XhoI and ligated into pGALL-(HIS3). For mammalian and insect cell expression, MaviP35-F was amplified from pGALL-(HIS3)-MaviP35-F with oligonucleotides 8 and 7, then cut with BamHI/XhoI, blunted and inserted into pHSP70PLVIþ CAT (chloramphenicol acetyl transferase)35 cut with BglII/EcoRI blunted or pEF 36 cut with BamHI/XbaI blunted. Caspase 3 was amplified using primers 9 and 10, then digested with NdeI/XhoI and ligated into NdeI/XhoI cut pET23a. All amplified fragments were sequenced to verify the absence of any unintentional mutations. The pAct5cGFP vector was kindly provided by Samuel Le Fort and David Vaux. The coding sequencing of DRICEC211A was amplified from pGMR-DRICE with primers 11 and 12, cut with BglII and cloned into pACT5cGFP cut with BamHI to generate pACT5c-DRICEC211A-eGFP. Restriction analyses and sequencing were performed to determine the orientation of the insert and to check the sequence was correct. pGMR-DRICE was made by amplifying DRICE with primers 13 and 14, then cutting the product with BglII and XbaI and cloning into pGMR cut with NheI and NotI. The DNA encoding eGFP was removed from pAct5cGFP by cutting with BamHI and XbaI, blunting using Klenow polymerase and religating to yield pAct5c. Boll/XhoI fragments encoding either DIAP1 (obtained by digesting pGALL-(HIS3)-DIAP1) or MaviP35-FLAG (excised from pGALL-(HIS3)-MaviP35-F) were ligated into Boll/XhoI cut pAct5c-gfp, replacing the eGFP gene.

The sequences of the nucleotides referred to above were as follows:

1: 5’-CGGGATCCATGGCCGACAAGGTCCTGAAGGAG-3’
2: 5’-GCTCTAGATTAATGTCCTGGGAAGAGGTAGAAACATC-3’
3: 5’-GGGATCCATATGTGTGTAATTTTTCCAGTAG-3’

Figure 6 MaviP35 is cleaved by DRONC but does not inhibit DRONC activity in vitro. (a) Yeast were transformed with the indicated expression plasmids. Suspensions containing equivalent concentrations of each transformant were serially diluted, and 5 μl of each dilution were spotted onto inducing and repressing plates. A total of 400 ng of FLAG-tagged MaviP35 (b) or AcP35 (c) were incubated with 0, 15, 150 or 1500 nM of DRONC or DRICE, then processing was monitored by anti-FLAG immunoblotting. (d) Drosophila Kc167 cells were co-transfected with a plasmid encoding either eGFP or DRICEC211A-eGFP, together with either an empty vector or plasmid directing expression of AcP35-F, MaviP35-FLAG or DIAP1. Transfectants were incubated in media containing or lacking 1 μM actinomycin D (ActD) for 12 h. Lysates were subjected to anti-GFP or anti-FLAG immunoblotting, or coomassie staining. (e) The structure of the DRICEC211A-eGFP fusion protein is shown. (f) Cleavage of Ac-TQTD-AFC by purified recombinant DRONC is plotted as the change in RFU per minute, in the presence of 1.6 μM of FLAG-tagged MaviP35, AcP35 or truncated CED-9.
Characterization of MaviP35
IL Brand et al

Figure 7 MaviP35 is an efficient inhibitor of executioner caspases in vitro. Purified FLAG-tagged MaviP35 and AcP35 were tested in vitro for their ability to inhibit cleavage of fluorogenic peptide substrates by human caspases 3, 8 and 9 and Drosophila DRICE and DRONC. Hydrolysis of the indicated substrates was monitored in the presence of a range of inhibitor concentrations. Graphs show the impact of various caspase concentrations. Graphs (a) and (b) show activity (ARFU/min) of caspases 3, 8, and 9, respectively. Inhibition constants (Ki) were calculated for selected caspases using a competitive model, as described in the Materials and Methods.

4: 5’-GCTCTGAGTAACTATGTTATTTATATTTATG’-3’
5: 5’-GCTCTGAGTAACTATGTTATTTATATTTATG’-3’
6: 5’-CATTTGATCAACTAGAACGCGACCACAGCTCATTGCTGACGGGCC’-3’
7: 5’-CTTTATTATTTATTTATATTTATGAGGGGTTG’-3’
8: 5’-GCCGATCCACCGTATGTTATTTATTTATGAGGGCC’-3’
9: 5’-GAATTCCTATGAGAGACCTAATCCAATGAG’-3’
10: 5’-CCCTCGAGGATCAATAATGAGAGTCCTTTTGAGGTAC’-3’
11: 5’-GTCGACTCTCAAATGAGGCGACATAACACTGAG’-3’
12: 5’-GTCGATCTACCCGTCGAGGAGGACAC’-3’
13: 5’-CGAGATCCGTCGGCCTGACGGCACCAC’-3’
14: 5’-CGTCTACATGTAACCCTCGCCTGACGGCACCAC’-3’
15: 5’-CTTGACTGAGCCTGCAAGGCACTTCAATGAGGACAC’-3’
16: 5’-GCACTATGTGCGGCGGCTCAACCCGTCGCCTGAGCCACAC’-3’

Apoptosis assays from insect cells. Sf21 cells were plated at 8 x 10^5 cells per well in six-well plates in TC-100 insect medium (Invitrogen, Carlsbad, CA, USA) plus 10% fetal bovine serum (FBS; Atlanta Biologicals, Atlanta, GA, USA), and allowed to attach overnight at 27°C. Transfections were performed using lipofectin, which was prepared as a 1:5:1 mixture of DOTAP ((N-(1-(2,3-Dioleyloxy)propyl)-N,N,N-trimethylammonium chloride salt; Avanti Polar Lipids, Alabaster, AL, USA) and DOPE (L-α-Dioleoyloxy)propyl)-N,N,N-trimethylammonium chloride salt; Avanti Polar Lipids, Alabaster, AL, USA) and 10% fetal bovine serum (FBS; Atlanta Biologicals, Atlanta, GA, USA) and 10% fetal bovine serum (FBS; Atlanta Biologicals, Atlanta, GA, USA) and allowed to incubate at 27°C for 4 h. The mixture plus the media was removed and 2 ml of TC-100 plus 10% FBS was added to each well. The cells were then induced to undergo apoptosis by treatment with either UV (by placing the plates on a transilluminator for 10 min) or actinomycin D (Invitrogen; 250 ng/ml). To determine cell viability, the number of GFP-expressing cells was counted in each well both immediately before and 17 h after UV or actinomycin D treatment. Three random fields of view per sample were counted per well, and three separate wells were assayed per treatment.

To assess sensitivity to infection-mediated apoptosis, Sf9 cells (10^5) were plated in six-well culture dishes for 2 h in the TC-100 medium with 10% FBS. After 2 h, the medium was replaced with Grace's insect unsupplemented medium (Invitrogen). Cells were transiently transfected with phSP70PLVII-CAT, phSP70PLVII-AcP35 or phSP70PLVII-MaviP35 using 3 μg of each plasmid and 6 μl of lipofectin. Transfection mixtures were replaced with TC-100 plus 10% FBS after 5 h incubation with cells. Cells were infected at 24 h post transfection with vAcP35KO-PG1 at a multiplicity of infection of 1 PFU/cell, and then harvested at 48 h post infection for caspase and viability assays. Caspase assays were performed using the substrate Ac-DEVD-AFC (MP Biomedicals, Solon, OH, USA) as described previously. To assess viability, three random fields of view were photographed ( x 200 magnification), and viable cells were counted for each well. Cell viability was determined by counting the non-apoptotic cells and comparing to the number of viable cells in a mock-infected control at 0 h post infection, which was set at 100.

DRICE cleavage assays in Kc167 cells. Two million Kc167 cells (kindly provided by Gary Hime) were transfected with 0.2 μg of either pAct5c-eGFP or pAct5c-DRICE-eGFP plus 1.8 μg of either pAc56c or pAc56c-MaviP35 or pAc56c-DRICE-DIAP1, using the Effectene transfection reagent (Qiagen, Doncaster, Victoria, Australia) according to the manufacturer's instructions. After 24 h transfection, the cells were incubated in media containing 0 or 1 μM of actinomycin D for 12 h. Cells were lysed in mammalian lysis buffer (50 mM Tris pH 7.5, 375 mM NaCl, 1 mM ethylenediamine tetra-acetic acid, 1% Triton X-100) containing protease inhibitors (protease inhibitor cocktail set 1; Calbiochem, Darmstadt, Germany) and subjected to 12% SDS-PAGE and either Coomassie stained or immunoblotted using anti-GFP (Roche Applied Science no. 1181446001; Castle Hill, New South Wales, Australia) or anti-FLAGM2 (Sigma no. F3165) and anti-mouse IgG-HRP (Sigma no. A9044).
Mammalian apoptosis assays. SV-40 transformed mouse embryonic fibroblasts (MEFs) were co-transfected with 1 μg of CMV-ires-Z and either 3 μg of pEF, AcP35-pEF or MaviP35-pEF using FuGENE HD transfection reagent (Roche; Basel, Switzerland). LN18 glioblastoma cells (ATCC; Manassas, VA, USA) were co-transfected with 1 μg of CMV-ires-Z and either 2 μg of pEF, AcP35-pEF or MaviP35-pEF using Lipofectamine (Invitrogen). Transfections were performed according to the manufacturers’ instructions. Twenty-four hours after transfection, the medium was removed and the cells were incubated with fresh unsupplemented media or media containing cisplatin (Mayne Pharma, Mulgrave, Victoria, Australia) or Superkiller (crosslinked) TRAIL (Aleo Biochemicals, Lausen, Switzerland). After 24 h, the cells were stained with 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside and the blue cells were scored for viable versus apoptotic morphology, as previously published.36

Yeast transformation and death assays. Saccharomyces cerevisiae yeast strain W303 was transformed37 and analyzed in survival assays3 as described previously.10 Caspase 1 was expressed using the pGALL-(LEU2)-Casp1 vector described above.

Protein assays from yeast. Yeast transformants were grown and transgene expression induced as described previously.11 The lysates were subjected to SDS-PAGE and the gels were then stained with Coomassie brilliant blue (Sigma) to visualize protein loading and immobiloblotted as described previously.11 The membranes were probed with an antibody recognizing the FLAG tag (clone M2; Sigma) and anti-mouse-HRP (Sigma). To measure the caspase activity via fluorescence analysis, the yeast were treated as follows: An overnight culture was pelleted, washed twice with 1 ml of TE and resuspended in 1 l of glucose-containing selective medium to stationary phase, then expanded by addition of media or media containing cisplatin (Mayne Pharma, Mulgrave, Victoria, Australia) or Superkiller (crosslinked) TRAIL (Aleo Biochemicals, Lausen, Switzerland). After 24 h, the yeast culture, the yeast was weighed and glass beads were added. To lyse the cells, 5 ml of CelLyticY reagent (Sigma) with 10 mM DTT was added per 1 g of yeast cells. After gently shaking the cells for 30 min at RT, the debris was removed by centrifugation at 16 100 g, 4 C for 15 min then glass beads were added after weighing the pellets. To lyse the cells CelLyticY reagent (Sigma) (with 10 mM DTT) was added per 1 g of yeast cells. After gently shaking the cells for 30 min at RT, the debris was removed by centrifugation at 16 100 g, 4 C for 15 min then glass beads were added after weighing the pellets. To lyse the cells CelLyticY reagent (Sigma) was used as described above. The supernatant was measured using the Bicinchoninic acid protein assay kit (Sigma). In fluorescence assays, lysate (0.5 mg/ml) was mixed with Ac-DEVD-AFC (100 μM) or Ac-EDVD-AFC (100 μM) in DRICE activity buffer (50 mM HEPES pH 7.5, 10% sucrose, 0.1% CHAPS, 5 mM DTT, 100 mM NaCl, 1 mM EDTA) and the fluorescence (excitation 410 nm, emission 500 nm) was measured every 30 s for 1 h. The slope of each curve was calculated using Graphpad Prism 5.0 (La Jolla, CA, USA). The slope of each curve determines the concentration of free AFC per minute, which provides a measure of caspase activity.

Protein purification from yeast. Transformants were grown in 5 ml glucose-containing selective medium to stationary phase, then expanded by addition of media or media containing cisplatin (Mayne Pharma, Mulgrave, Victoria, Australia) or Superkiller (crosslinked) TRAIL (Aleo Biochemicals, Lausen, Switzerland). After 24 h, the yeast culture, the yeast was weighed and glass beads were added. To lyse the cells CelLyticY reagent (Sigma) with 10 mM DTT was added per 1 g of yeast cells. After gently shaking the cells for 30 min at RT, the debris was removed by centrifugation at 16 100 g, 4 C for 15 min then glass beads were added after weighing the pellets. To lyse the cells CelLyticY reagent (Sigma) was used as described above. The supernatant was measured using the Bicinchoninic acid protein assay kit (Sigma). In fluorescence assays, lysate (0.5 mg/ml) was mixed with Ac-DEVD-AFC (100 μM) or Ac-EDVD-AFC (100 μM) in DRICE activity buffer (50 mM HEPES pH 7.5, 10% sucrose, 0.1% CHAPS, 5 mM DTT, 100 mM NaCl, 1 mM EDTA) and the fluorescence (excitation 410 nm, emission 500 nm) was measured every 30 s for 1 h. The slope of each curve was calculated using Graphpad Prism 5.0 (La Jolla, CA, USA). The slope of each curve determines the concentration of free AFC per minute, which provides a measure of caspase activity.

Determination of inhibition constants. Caspases were pre-activated for 10 min at 37 C in the following buffers: caspase 3: 100 mM HEPES pH 7.0, 10% PEG, 0.1% CHAPS, 10 mM DTT; caspase 5: 10 mM DTT; caspase 6: 50 mM HEPES pH 7.5, 10% sucrose, 0.1% CHAPS, 5 mM DTT, 100 mM NaCl, 1 mM EDTA; caspases 7 and 8: 10 mM HEPES pH 7.0, 10% sucrose, 0.1% CHAPS, 10 mM DTT, 100 mM NaCl, 0.1 mM EDTA, 0.65 M Na-Citrate; DRONC: 50 mM Tris pH 7.4, 100 mM NaCl, 0.65 M Na-Citrate. Subsequently, the caspase was incubated with either AcP35-F or MaviP35-F in the appropriate activity buffer for 1 h at 37 C. The appropriate fluorescent substrate was then added (100 μM): Ac-WEHD-afc for caspase 1; Ac-VDAD-afc for caspases 2; Ac-DEVD-afc for caspases 3, 7, DRICE; DCP-1 and CED-3; Ac-VEID-afc for caspase 8; Ac-LEHD-afc for caspases 9, 10 and 10 and Ac-TQTD-afc for DRONC (Enzo Life Sciences). Fluorescence (excitation 410 nm, emission 500 nm) was measured every minute for 2 h. The maximal slope of each curve was calculated using Prism 5.0 and graphed.

Conflict of Interest

The authors declare no conflict of interest.

Acknowledgements. We thank Chung-Hsiung Wang for providing the plasmid bearing the MaviP35 gene, Sam Le Fort and David Vaux for the pEctiT-c

GFPL plasmid, Gary Heme for the Kc167 cells and Anissa Jabbour and Paul Eckart for the MEF cells. This work was funded by the National Health and Medical Research Council project grant to CWH and RJ (NHMRC 602255; an Australian Research Council Future Fellowship to CWH (#FT0991464), scholarships to ILB and MML from the La Trobe University and a scholarship to ILB from the Cooperative Research Centre for Biomarker Translation.

1. Ameisen JC. On the origin, evolution, and nature of programmed cell death: a timeline of four billion years. Cell Death Difference. 1999;6:373–303.
2. Best SM. Viral subversion of apoptotic enzymes: escape from death row. Annu Rev Microbiol. 2006;62:171–192.
3. Jabbour AM, Hawkins CJ. The p35 family of apoptosis inhibitors. Curr Genomics 2004;5:215–229.
4. Measys C, Penabat T, Clem RJ. Identification and functional characterization of AMP-33, a novel homolog of the baculovirus caspase inhibitor p35 found in Amsacta morei entomopoxivirus. Virology 2007; 358: 436–447.

5. Hemiot EA, Osiaszewski JA, O'Reilly DR, Cory JS. Ancient coevolution of baculoviruses and their insect hosts. J Virol 2004; 78: 3244–3251.

6. Clem RJ, Fechheimer M, Miller FK. Prevention of apoptosis by a baculovirus gene during infection of insect cells. Science 1991; 254: 1386–1390.

7. Xi G, Rich RL, Stegborn C, Min T, Huang Y, Myzika DG et al. Mutational analyses of the p30-caspase interaction. A bowstring kinetic model of caspase inhibition by p35. J Biol Chem 2003; 278: 5455–5461.

8. Xi G, Cirihi M, Huang Y, Rich RL, Myzika DG, Wu H. Covalent inhibition revealed by the crystal structure of the caspase-8/p35 complex. Nature 2001; 410: 494–497.

10. Meier P, Silke J, Leevers SJ, Evan GI. The baculovirus caspase DIAP1 is regulated by DIAP1. EMBO J 2000; 19: 598–611.

11. Hawkins CJ, Yoo SJ, Petersen EP, Wang SL, Vermyoo SY, Hay BA. The baculovirus caspase DIAP1 cleaves following glutamate or aspartate and is regulated by DIAP1, HID, and GRIM. J Biol Chem 2000; 275: 27084–27092.

12. Lacey MG, Hanson SF, Schneider CL, Friesen PD. Caspase Inhibitor p35 and inhibitor of apoptosis Op-IAP block virus induced apoptosis downstream of effector caspase DrICE activation in Drosophila cells. J Biol Chem 2001; 276: 13274–13280.

13. Vier J, Furmann C, Hacker G. Baculovirus protein does not inhibit caspase-9 in a cell-free system of apoptosis. Biochem Biophys Res Commun 2000; 276: 855–861.

14. Morishima N, Okano K, Shibata T, Maeda S. Homologous p35 proteins of baculoviruses show distinctive anti-apoptotic activities which correlate with the apoptosis-inducing activity of each virus. FEBS Lett 1998; 427: 144–148.

15. Kamata SG, Majma K, Maeda S. Identification and characterization of the p35 gene of Bombyx mori nuclear polyhedrosis virus that prevents virus-induced apoptosis. J Virol 1993; 67: 455–463.

16. Gomi S, Zhou CE, Yih W, Majma K, Maeda S. Deletion analysis of four of eighteen gene expression factors homologues of the baculovirus, BmNPV. Virology 1997; 230: 35–47.

17. Pei Z, Reske G, Huang Q, Harrold BD, Qi Y, Chejanovsky N. Characterization of the apoptosis suppressor protein P49 from the Spodoptera liturae illicitoris DNA virus. J Biol Chem 2002; 277: 48677–48684.

18. Zorg SJ, Schiller JJ, Wetter JA, Chejanovsky N, Friesen PD. Baculovirus apoptotic suppressor P49 is a substrate inhibitor of initiator caspases resistant to p35 in vivo. EMBO J 2002; 21: 5130–5140.

19. Lannen E, Vandenhaute R, Friesen PD. Baculovirus caspase inhibitors P49 and P38 block virus-induced apoptosis downstream of effector caspase DrICE activation in Drosophila melanogaster cells. J Biol Chem 2001; 276: 3931–3935.

20. Guy MP, Friesen PD. Reductive-site cleavage residues confer target specificity to baculovirus P49, a dimeric member of the P35 family of caspase inhibitors. J Biol Chem 2008; 283: 7504–7514.

21. Jabbour AM, Ekert PG, Coulson EJ, Knight MJ, Ashley DM, Hawkins CJ. The p35 relative, p49, inhibits mammalian and Drosophila caspases including DIAP1 and protects against apoptosis. Cell Death Differ 2002; 9: 1311–1320.

22. Lee S-T, Srinivasan R, Lo Y-J, Talekar NS. Identification, characterization and bioassays of Manica vulgaris multiple nucleopolyhedrovirus (MavNPV) against Manica vulgaris (Lepidoptera, Pyralidae). BioControl 2007; 52: 801–809.

23. Chen YR, Wu CY, Lee ST, Wu YJ, Lo CF, Tsai MF et al. Genomic and host range studies of Manica vulgaris nucleopolyhedrovirus. J Gen Virol 2008; 89: 2315–2330.

24. Fisher AJ, Cruz W, Zhao SJ, Schneider CL, Friesen PD. Crystal structure of baculovirus P35: role of a novel reactive site loop in apoptotic caspase inhibition. EMBO J 1999; 18: 2031–2039.

25. Bertin J, Mendrysa SM, Lacourt DJ, Gaur S, Krebs JF, Armstrong RC et al. Apoptotic suppression by baculovirus P35 involves cleavage and inhibition of a virus-induced Apaf-1-like protease. J Virol 1995; 69: 6251–6259.

26. Zhou Q, Krebs J, Snipas S, Price A, Ahlemir E, Tomasselli G et al. Interaction of the baculovirus anti-apoptotic protein p35 with caspases. Specificity, kinetics, and characterization of the caspase-p35 complex. Biochemistry 1998; 37: 10757–10765.

27. Donort L, Read S, Cakurova D, Huh JR, Hay BA, Kumar S. The role of cytochrome c in caspase activation in Drosophila melanogaster cells. J Cell Biol 2002; 156: 1093–1098.

28. Corpet F. Multiple sequence alignment with hierarchical clustering. Nucleic Acids Res 1988; 16: 10811–1089.

29. Waterhouse AM, Procter JB, Martin DM, Clamp M, Barton GJ. Jalview Version 2 – a multiple alignment editor and analysis workbench. Bioinformatics 2009; 25: 1189–1191.

30. Kelley LA, Stemberg MJ. Protein structure prediction on the Web: a case study using the Phyre server. Nat Protoc 2009; 4: 363–371.

31. Hawkins CJ, Wang SL, Hay BA. Monitoring activity of caspases and their regulators in yeast Saccharomyces cerevisiae. Methods Enzymol 2000; 322: 162–174.

32. Hawkins CJ, Wang SL, Hay BA. A cloning method to identify caspases and their regulators in yeast: identification of Drosophila IAP1 as an inhibitor of the Drosophila caspase DCP-1. Proc Natl Acad Sci 1999; 96: 2885–2890.

33. Hawkins CJ, Sijouz J, Verhagen AM, Foster R, Ekert PG, Ashley DM. Analysis of candidate antagonists of IAP-mediated caspase inhibition using yeast reconstituted with the mammalian Apaf-1-activated apoptosis mechanism. Apoptosis 2001; 6: 331–338.

34. Jabbour AM, Ho PK, Puryer MA, Ashley DM, Ekert PG, Hawkins CJ. The Caenorhabditis elegans CED-9 protein does not directly inhibit the caspase CED-3, in vitro nor in yeast. Cell Death Differ 2004; 11: 1309–1316.

35. Clem RJ, Miller IK. Control of programmed cell death by the baculovirus genes p35 and IAP. Mol Cell Biol 1994; 14: 5212–5222.

36. Hawkins CJ, Uen AG, Hacker G, Medcalf RL, Vaux DL. Inhibition of interleukin 1-beta converting enzyme-mediated apoptosis of mammalian cells by baculovirus IAP. Proc Natl Acad Sci USA 1996; 93: 13786–13790.

37. Hay BA, Wolf T, Rubin GM. Expression of baculovirus P35 prevents cell death in Drosophila. Development 1994; 120: 2121–2129.

38. Clarke TE, Clem RJ. Lack of involvement of haemocytes in the establishment and spread of infection in Spodoptera frugiperda larvae infected with the baculovirus Autographa californica M nucleopolyhedrosis virus by intraheemocoelic injection. J Gen Virol 2002; 83: 1593–1572.

39. Huang N, Wu W, Yang K, Passarelli AL, Rohrmann GF, Clem RJ. Baculovirus infection induces a DNA damage response that is required for efficient viral replication. J Virol 2011; 85: 12547–12556.

40. Wang H, Blair CD, Olson KE, Clem RJ. Effects of inducing or inhibiting apoptosis on Sindbis virus replication in mosquito cells. J Gen Virol 2008; 89: 2651–2661.